TY - JOUR
T1 - Obesity, adiposity, and dyslipidemia
T2 - A consensus statement from the National Lipid Association
AU - Bays, Harold E.
AU - Toth, Peter P.
AU - Kris-Etherton, Penny M.
AU - Abate, Nicola
AU - Aronne, Louis J.
AU - Brown, W. Virgil
AU - Gonzalez-Campoy, J. Michael
AU - Jones, Steven R.
AU - Kumar, Rekha
AU - La Forge, Ralph
AU - Samuel, Varman T.
N1 - Funding Information:
Dr. Gonzalez-Campoy has received honoraria related to speaking from the American Association of Clinical Endocrinologists, Santarus, International Society of Clinical Densitometrists, Consensus Medical Communications, Eastern European Medical Society, Boehringer Ingelheim, Forest Laboratories, Hennepin County Medical Center, Council of State Bioscience Associations (CSBA), Amylin, OurCreatus, and Tethys. Dr. Gonzalez-Campoy has received research grants from Sanofi-Aventis, Novo Nordisk, Leptos, MNCOME Foundation, AstraZeneca, Boehringer Ingelheim, Ipsen, Eli Lilly & Co., and Bristol-Myers Squibb. Dr. Gonzalez-Campoy has received consulting fees from the National Institutes of Health, Centers for Disease Control, National Diabetes Education Program, Merck & Co., National Minority Quality Forum, Pfizer Inc., Leptos, Medtronic, Consensus Medical Communications, Roche, Shindler-Neff (law firm), Kitch Attorneys and Counselors, WebMD/Medscape, Boehringer Ingelheim, EndocrineWeb, Allergan, Tethys, Amylin, and ValenTx.
Funding Information:
Dr. Bays has received honoraria related to speaking from Amarin Corp., Bristol-Myers Squibb, Daiichi Sankyo Inc., Eisai, Merck & Co., and VIVUS. Dr. Bays has received honoraria related to consulting from Amarin Corp., Amgen, AstraZeneca, Catabasis, WPU, and Zeomedex. Dr. Bays has received research grants from Alere, Amarin Corp., Amgen, Ardea Inc., Arena Pharmaceuticals, Boehringer Ingelheim, California Raisin Board, Cargill, Eisai, Elcelyx, Esperion, Essentialis, Forest Laboratories, Gilead Sciences Inc., Given, GlaxoSmithKline, High Point, Hoffman LaRoche, Home Access, Micropharma, Merck & Co., Nektar, Novartis, Novo Nordisk, Omthera, Orexigen, Pfizer Inc., Pozen, Regeneron, Stratum Nutrition, Takeda Pharmaceuticals, TIMI, Transtech Pharma Inc., Trygg, TWI Bio, VIVUS, WPU, and Xoma.
PY - 2013/7
Y1 - 2013/7
N2 - The term "fat" may refer to lipids as well as the cells and tissue that store lipid (ie, adipocytes and adipose tissue). "Lipid" is derived from "lipos," which refers to animal fat or vegetable oil. Adiposity refers to body fat and is derived from "adipo," referring to fat. Adipocytes and adipose tissue store the greatest amount of body lipids, including triglycerides and free cholesterol. Adipocytes and adipose tissue are active from an endocrine and immune standpoint. Adipocyte hypertrophy and excessive adipose tissue accumulation can promote pathogenic adipocyte and adipose tissue effects (adiposopathy), resulting in abnormal levels of circulating lipids, with dyslipidemia being a major atherosclerotic coronary heart disease risk factor. It is therefore incumbent upon lipidologists to be among the most knowledgeable in the understanding of the relationship between excessive body fat and dyslipidemia. On September 16, 2012, the National Lipid Association held a Consensus Conference with the goal of better defining the effect of adiposity on lipoproteins, how the pathos of excessive body fat (adiposopathy) contributes to dyslipidemia, and how therapies such as appropriate nutrition, increased physical activity, weight-management drugs, and bariatric surgery might be expected to impact dyslipidemia. It is hoped that the information derived from these proceedings will promote a greater appreciation among clinicians of the impact of excess adiposity and its treatment on dyslipidemia and prompt more research on the effects of interventions for improving dyslipidemia and reducing cardiovascular disease risk in overweight and obese patients.
AB - The term "fat" may refer to lipids as well as the cells and tissue that store lipid (ie, adipocytes and adipose tissue). "Lipid" is derived from "lipos," which refers to animal fat or vegetable oil. Adiposity refers to body fat and is derived from "adipo," referring to fat. Adipocytes and adipose tissue store the greatest amount of body lipids, including triglycerides and free cholesterol. Adipocytes and adipose tissue are active from an endocrine and immune standpoint. Adipocyte hypertrophy and excessive adipose tissue accumulation can promote pathogenic adipocyte and adipose tissue effects (adiposopathy), resulting in abnormal levels of circulating lipids, with dyslipidemia being a major atherosclerotic coronary heart disease risk factor. It is therefore incumbent upon lipidologists to be among the most knowledgeable in the understanding of the relationship between excessive body fat and dyslipidemia. On September 16, 2012, the National Lipid Association held a Consensus Conference with the goal of better defining the effect of adiposity on lipoproteins, how the pathos of excessive body fat (adiposopathy) contributes to dyslipidemia, and how therapies such as appropriate nutrition, increased physical activity, weight-management drugs, and bariatric surgery might be expected to impact dyslipidemia. It is hoped that the information derived from these proceedings will promote a greater appreciation among clinicians of the impact of excess adiposity and its treatment on dyslipidemia and prompt more research on the effects of interventions for improving dyslipidemia and reducing cardiovascular disease risk in overweight and obese patients.
KW - Adiposity
KW - Adiposopathic dyslipidemia
KW - Adiposopathy
KW - Dyslipidemia
KW - High-density lipoprotein
KW - Insulin resistance
KW - Low-density lipoprotein
KW - Obesity
KW - Triglycerides
KW - Type 2 diabetes mellitus
UR - http://www.scopus.com/inward/record.url?scp=84880917866&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84880917866&partnerID=8YFLogxK
U2 - 10.1016/j.jacl.2013.04.001
DO - 10.1016/j.jacl.2013.04.001
M3 - Article
C2 - 23890517
AN - SCOPUS:84880917866
SN - 1933-2874
VL - 7
SP - 304
EP - 383
JO - Journal of Clinical Lipidology
JF - Journal of Clinical Lipidology
IS - 4
ER -